Featured Research

from universities, journals, and other organizations

Why some experimental forms of 'The Pill for Males' will never rise to the occasion

Date:
June 2, 2014
Source:
Federation of American Societies for Experimental Biology
Summary:
It appears that 'The Pill' for men will have to wait a while longer. A new research study involving mice shows that a previously developed male hormonal oral contraceptive method (i.e. via testosterone) is unable to stop the production and/or release of sperm. Scientists demonstrated that the male contraception approach by testosterone has an inherent problem -- spermatogenesis does not stop. They found that that administering increasing doses of testosterone to infertile mutant mice did allow sexual function to return at a certain dosing threshold, however spermatogenesis also returned at that dose.

It appears that "The Pill" for men will have to wait a while longer. A new research report published in the June 2014 issue of The FASEB Journal involving mice, shows that a previously developed male hormonal oral contraceptive method (i.e. via testosterone) is unable to stop the production and / or the release of sperm.

"Our research in mice explains why the efficacy of male hormonal contraception is not as effective as expected and it provides clues on how to improve the method," said Ilpo Huhtaniemi, M.D., Ph.D., M.D.hc, FMed.Sci., a researcher involved in the work from the Institute of Reproductive and Developmental Biology at the Imperial College of London in London, UK.

Scientists demonstrated in experimental mice that the male contraception approach by testosterone has an inherent problem -- spermatogenesis does not stop. They found that that administering increasing doses of testosterone to infertile mutant mice did allow sexual function to return at a certain dosing threshold, which was expected. What was not expected, however, is that spermatogenesis also returned at that dose. This suggests that it is impossible to give a single dose of testosterone that allows for sexual function and the suppression of pituitary gonadotropin secretion, but also does not initiate sperm production.

"Ever since The Pill was developed, we've been aiming for an equivalent for men," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This report suggests that we may be finally reaching the end of administering testosterone for this purpose."


Story Source:

The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. O. O. Oduwole, N. Vydra, N. E. M. Wood, L. Samanta, L. Owen, B. Keevil, M. Donaldson, K. Naresh, I. T. Huhtaniemi. Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception. The FASEB Journal, 2014; 28 (6): 2566 DOI: 10.1096/fj.13-249219

Cite This Page:

Federation of American Societies for Experimental Biology. "Why some experimental forms of 'The Pill for Males' will never rise to the occasion." ScienceDaily. ScienceDaily, 2 June 2014. <www.sciencedaily.com/releases/2014/06/140602101704.htm>.
Federation of American Societies for Experimental Biology. (2014, June 2). Why some experimental forms of 'The Pill for Males' will never rise to the occasion. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140602101704.htm
Federation of American Societies for Experimental Biology. "Why some experimental forms of 'The Pill for Males' will never rise to the occasion." ScienceDaily. www.sciencedaily.com/releases/2014/06/140602101704.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins